SRDX Surmodics Inc
Price (delayed)
$39.49
Market cap
$563.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.09
Enterprise value
$568.62M
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics
Highlights
The net income has dropped by 110% since the previous quarter but it has surged by 94% year-on-year
The company's EPS has shrunk by 109% QoQ but it has surged by 95% YoY
The gross profit is down by 21% since the previous quarter and by 16% year-on-year
SRDX's revenue is down by 15% QoQ and by 7% YoY
Key stats
What are the main financial stats of SRDX
Market
Valuations
Earnings
Shares outstanding
14.27M
Market cap
$563.4M
Enterprise value
$568.62M
Price to book (P/B)
4.77
Price to sales (P/S)
4.63
EV/EBIT
N/A
EV/EBITDA
146.89
EV/Sales
4.71
Revenue
$120.82M
EBIT
-$5.61M
EBITDA
$3.87M
Free cash flow
-$5.86M
Per share
Balance sheet
Liquidity
EPS
-$0.09
Free cash flow per share
-$0.41
Book value per share
$8.28
Revenue per share
$8.53
TBVPS
$7.79
Total assets
$177.41M
Total liabilities
$59.27M
Debt
$29.52M
Equity
$118.14M
Working capital
$60.16M
Debt to equity
0.25
Current ratio
3.98
Quick ratio
2.55
Net debt/EBITDA
1.35
Margins
Efficiency
Dividend
EBITDA margin
3.2%
Gross margin
74%
Net margin
-1.2%
Operating margin
-6.2%
Return on assets
-0.8%
Return on equity
-1.2%
Return on invested capital
-6.1%
Return on capital employed
-3.6%
Return on sales
-4.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRDX stock price
How has the Surmodics stock price performed over time
Intraday
0.59%
1 week
0.66%
1 month
-1.42%
1 year
16.9%
YTD
8.64%
QTD
-6.07%
Financial performance
How have Surmodics's revenue and profit performed over time
Revenue
$120.82M
Gross profit
$89.43M
Operating income
-$7.48M
Net income
-$1.4M
Gross margin
74%
Net margin
-1.2%
SRDX's operating margin has dropped by 148% since the previous quarter
The operating income has plunged by 141% from the previous quarter
The net margin has dropped by 113% since the previous quarter but it has soared by 93% year-on-year
The net income has dropped by 110% since the previous quarter but it has surged by 94% year-on-year
Growth
What is Surmodics's growth rate over time
Valuation
What is Surmodics stock price valuation
P/E
N/A
P/B
4.77
P/S
4.63
EV/EBIT
N/A
EV/EBITDA
146.89
EV/Sales
4.71
The company's EPS has shrunk by 109% QoQ but it has surged by 95% YoY
The stock's price to book (P/B) is 16% more than its last 4 quarters average of 4.1 and 8% more than its 5-year quarterly average of 4.4
Surmodics's equity has increased by 5% YoY but it has decreased by 4.7% QoQ
SRDX's P/S is 24% above its last 4 quarters average of 3.7 but 12% below its 5-year quarterly average of 5.2
SRDX's revenue is down by 15% QoQ and by 7% YoY
Efficiency
How efficient is Surmodics business performance
The company's return on sales has shrunk by 132% QoQ
The ROIC has plunged by 125% from the previous quarter
SRDX's return on assets has dropped by 111% since the previous quarter but it has surged by 94% year-on-year
The ROE has plunged by 111% from the previous quarter but it has soared by 94% YoY
Dividends
What is SRDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRDX.
Financial health
How did Surmodics financials performed over time
The total assets is 199% more than the total liabilities
The current ratio has grown by 49% YoY but it has contracted by 9% from the previous quarter
SRDX's quick ratio is up by 45% year-on-year but it is down by 8% since the previous quarter
The debt is 75% smaller than the equity
Surmodics's equity has increased by 5% YoY but it has decreased by 4.7% QoQ
The debt to equity has grown by 4.2% from the previous quarter but it has contracted by 3.8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.